US09058V1035 - Common Stock
7.34 -0.01 (-0.14%)
BIOCRYST PHARMACEUTICALS INC
NASDAQ:BCRX (9/27/2023, 11:17:05 AM)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The company is headquartered in Durham, North Carolina and currently employs 531 full-time employees. The firm focuses on oral treatments for rare diseases, in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), BCX9930, BCX9250, PERAMIFLU (peramivir injection), galidesivir, and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. BCX9930 is an oral, potent, and selective small molecule inhibitor of Factor D. Galidesivir is a broad-spectrum antiviral that is active against viral families.
BIOCRYST PHARMACEUTICALS INC
4505 Emperor Blvd Ste 200
Durham NORTH CAROLINA 27703
CEO: Jon P. Stonehouse
INTENDED FOR CANADIAN AUDIENCES ONLY...
DESTINÉ À UN AUDITOIRE CANADIEN SEULEMENT...
RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted five newly-hired employees stock options to purchase an aggregate of 28,300 shares, and restricted stock units (RSUs) covering an aggregate of 19,900 shares, of BioCryst common stock. The options and RSUs were granted as of August 31, 2023, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
These three biotech stocks are attractive buys right now.
RESEARCH TRIANGLE PARK, N.C., Aug. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...
Here you can normally see the latest stock twits on BCRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.